Terms: = Gastric cancer AND TCF7L2, ENSG00000148737, 6934, TCF-4 AND Prognosis
3 results:
1. tcf7l2 promotes anoikis resistance and metastasis of gastric cancer by transcriptionally activating PLAUR.
Zhang T; Wang B; Su F; Gu B; Xiang L; Gao L; Zheng P; Li XM; Chen H
Int J Biol Sci; 2022; 18(11):4560-4577. PubMed ID: 35864968
[TBL] [Abstract] [Full Text] [Related]
2. The Wnt3a/β-catenin/tcf7l2 signaling axis reduces the sensitivity of HER2-positive epithelial ovarian cancer to trastuzumab.
Shen G; Gao Q; Liu F; Zhang Y; Dai M; Zhao T; Cheng M; Xu T; Jin P; Yin W; Huang D; Weng H; Chen W; Ren H; Mu X; Wu X; Hu S
Biochem Biophys Res Commun; 2020 Jun; 526(3):685-691. PubMed ID: 32248976
[TBL] [Abstract] [Full Text] [Related]
3. Silencing of WISP3 suppresses gastric cancer cell proliferation and metastasis and inhibits Wnt/β-catenin signaling.
Fang F; Zhao WY; Li RK; Yang XM; Li J; Ao JP; Jiang SH; Kong FZ; Tu L; Zhuang C; Qin WX; He P; Zhang WM; Cao H; Zhang ZG
Int J Clin Exp Pathol; 2014; 7(10):6447-61. PubMed ID: 25400723
[TBL] [Abstract] [Full Text] [Related]
